ArticleBMC cancer2025
Telpegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in patients with high- or medium-risk non-myeloid malignancies: a multicenter, retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) pose significant risks in patients with non-myeloid malignancies. This study aimed to evaluate the efficacy and safety of telpegfilgrastim in CIN prevention.
methodsThis multicentre retrospective study enrolled 110 patients with high-/medium-risk non-myeloid malignancies receiving chemotherapy and telpegfilgrastim prophylaxis, and divided them into 2nd day (83 patients) and 3rd day (27 patients) groups. The primary outcome was the incidence of grade 3/4 CIN, whereas the secondary outcomes included FN incidence, antibiotic usage, and infection rate. Subgroup analyses were conducted for absolute neutrophil counts (ANC), primary/secondary prophylaxis, and single-/multicycle medication.
resultsThe incidence of grade 3/4 CIN was 5.59% in the 2nd day group and 8.89% in the 3rd day group. The 2nd day group reported no cases of FN, whereas the 3rd day group exhibited an incidence of 2.22%. Antibiotic usage and the incidence of infection were relatively lower in the 2nd day group. In the 2nd day group, ANC significantly increased to the normal level in the first cycle and remained higher than baseline after multiple cycles; however, the 3rd day group showed no significant change. In primary prophylaxis, the incidence of grade 3/4 CIN was 2.82% in the 2nd day group and 4.17% in the 3rd day group; in secondary prophylaxis, it was 7.78% and 14.29%, respectively, with an incidence rate ratio of 0.35 (P = 0.028) comparing primary to secondary prophylaxis. Bone pain was reported in one patient in each group, with no serious adverse events overall.
conclusionsTelpegfilgrastim administered on the 2nd and 3rd day after chemotherapy effectively reduced the risk of CIN and FN. Besides this, primary prophylaxis is more beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.